Guideline-Directed Treatment of Gastritis in Hospitalized Patients
For hospitalized patients with gastritis, initiate proton pump inhibitor (PPI) therapy for acid suppression and symptom relief, test for H. pylori infection, and if positive, treat with bismuth quadruple therapy as first-line eradication regimen.
Immediate Management
Acid Suppression
- Start PPI therapy immediately for mucosal healing and symptom control 1
- Alternative options include H2-receptor antagonists or potassium-competitive acid blockers (P-CABs), though PPIs remain standard 1
- Mucoprotective agents (such as rebamipide) can be added for enhanced mucosal protection through promoting regeneration and reducing inflammation 1, 2
H. pylori Testing and Treatment
All patients with gastritis must be assessed for H. pylori infection 3. This is critical because:
- H. pylori is responsible for most peptic ulcers and >80% of gastric cancers 4
- Eradication cures gastritis and prevents gastric cancer progression 4
First-Line H. pylori Eradication
Bismuth quadruple therapy is the preferred first-line treatment, replacing older clarithromycin-based triple therapy due to increasing antibiotic resistance 4. This regimen includes:
- PPI + bismuth + two antibiotics (typically metronidazole and tetracycline)
- Duration: 10-14 days
- Effective even with metronidazole-resistant strains 4
Alternative first-line option: Concomitant 4-drug therapy (PPI + clarithromycin + amoxicillin + metronidazole), particularly when bismuth is unavailable 4
Avoid clarithromycin-based triple therapy as first-line due to declining success rates from resistance 4
Confirmation of Eradication
- Confirm successful eradication using non-serological testing (stool antigen or urea breath test) 3
- Test at least 4 weeks after completing therapy
Specific Gastritis Subtypes
Atrophic Gastritis
If atrophic gastritis is suspected or confirmed:
Diagnostic workup:
- Obtain endoscopy with biopsies from body and antrum/incisura in separate jars 3
- Look for endoscopic features: pale mucosa, increased vascular visibility, loss of gastric folds 3
- Confirm diagnosis histopathologically 3
Additional testing:
- Screen for vitamin B12 and iron deficiencies (especially if corpus-predominant) 3
- Check antiparietal cell and anti-intrinsic factor antibodies if autoimmune gastritis suspected 3
- Screen for autoimmune thyroid disease in autoimmune gastritis 3
Surveillance:
- Advanced atrophic gastritis: endoscopy every 3 years 3
- Screen for type 1 gastric neuroendocrine tumors in autoimmune gastritis 3
Critical Pitfalls to Avoid
Do not rely on serological H. pylori testing for confirmation of eradication - use stool antigen or breath testing 3
Do not use previously failed antibiotics in subsequent eradication attempts - resistance to clarithromycin, levofloxacin, or metronidazole persists 4
Do not discontinue PPIs in patients with fundic gland polyps if there is a valid indication for PPI use 5
Do not miss intestinal metaplasia - its presence almost invariably indicates atrophic gastritis and requires risk stratification 3
Second-Line Treatment (If First-Line Fails)
If initial H. pylori eradication fails:
- Use levofloxacin triple therapy (PPI + amoxicillin + levofloxacin) if levofloxacin not previously used 4
- Alternative: bismuth quadruple therapy if not used first-line 4
- Reserve rifabutin-based triple therapy or high-dose dual PPI-amoxicillin for third-line 4
Hospital-Specific Considerations
For hospitalized patients specifically:
- Ensure NPO status is appropriate before endoscopy if diagnostic evaluation needed
- Coordinate with pathology for proper specimen handling (separate jars for different anatomic sites)
- Address nutritional deficiencies (B12, iron) before discharge if atrophic gastritis confirmed
- Arrange outpatient follow-up for eradication confirmation testing
- Document antibiotic allergies and previous H. pylori treatment attempts to guide regimen selection